 | • レポートコード：D0GIR-12202 • 出版社/出版日：GlobalInfoResearch / 2020年9月30日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール • 産業分類：医療、製薬、バイオ |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、神経障害薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。神経障害薬の種類別市場規模（抗精神病薬、催眠鎮静薬、鎮痛薬、抗凝固薬、その他）、用途別市場規模（病院、クリニック）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・メーカー情報（販売量、市場シェア、製品概要、SWOT分析）：Novartis AG、Bayer AG、GlaxoSmithKline plc、Teva Pharmaceutical、Merck & Co.、Boehringer Ingelheim GmbH、AstraZeneca ・地域別グローバル市場分析 2015年-2020年 ・神経障害薬の北米市場（アメリカ、カナダ、メキシコ） ・神経障害薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・神経障害薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・神経障害薬の南米市場（ブラジル、アルゼンチン） ・神経障害薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：抗精神病薬、催眠鎮静薬、鎮痛薬、抗凝固薬、その他 ・用途別分析：病院、クリニック ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Neurological Disorder Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.5% in the forecast period of 2020 to 2025 and will expected to reach USD 22730 million by 2025, from USD 19820 million in 2019.
The Neurological Disorder Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Neurological Disorder Drugs market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Neurological Disorder Drugs market has been segmented into
Antipsychotic
Hypnotic & Sedative
Analgesics
Anticoagulants
Others
By Application, Neurological Disorder Drugs has been segmented into:
Hospital
Clinic
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Neurological Disorder Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level Neurological Disorder Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Neurological Disorder Drugs market.
The report offers in-depth assessment of the growth and other aspects of the Neurological Disorder Drugs market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Neurological Disorder Drugs Market Share Analysis
Neurological Disorder Drugs competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Neurological Disorder Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Neurological Disorder Drugs sales, revenue and market share for each player covered in this report.
The major players covered in Neurological Disorder Drugs are:
Novartis AG
Bayer AG
GlaxoSmithKline plc
Teva Pharmaceutical
Merck & Co.
Boehringer Ingelheim GmbH
AstraZeneca
Among other players domestic and global, Neurological Disorder Drugs market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Neurological Disorder Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Neurological Disorder Drugs, with price, sales, revenue and global market share of Neurological Disorder Drugs in 2018 and 2019.
Chapter 3, the Neurological Disorder Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neurological Disorder Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Neurological Disorder Drugs market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Neurological Disorder Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Neurological Disorder Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Neurological Disorder Drugs Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Antipsychotic
1.2.3 Hypnotic & Sedative
1.2.4 Analgesics
1.2.5 Anticoagulants
1.2.6 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Neurological Disorder Drugs Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital
1.3.3 Clinic
1.4 Overview of Global Neurological Disorder Drugs Market
1.4.1 Global Neurological Disorder Drugs Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Novartis AG
2.1.1 Novartis AG Details
2.1.2 Novartis AG Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Novartis AG SWOT Analysis
2.1.4 Novartis AG Product and Services
2.1.5 Novartis AG Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Bayer AG
2.2.1 Bayer AG Details
2.2.2 Bayer AG Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Bayer AG SWOT Analysis
2.2.4 Bayer AG Product and Services
2.2.5 Bayer AG Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 GlaxoSmithKline plc
2.3.1 GlaxoSmithKline plc Details
2.3.2 GlaxoSmithKline plc Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 GlaxoSmithKline plc SWOT Analysis
2.3.4 GlaxoSmithKline plc Product and Services
2.3.5 GlaxoSmithKline plc Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Teva Pharmaceutical
2.4.1 Teva Pharmaceutical Details
2.4.2 Teva Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Teva Pharmaceutical SWOT Analysis
2.4.4 Teva Pharmaceutical Product and Services
2.4.5 Teva Pharmaceutical Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Merck & Co.
2.5.1 Merck & Co. Details
2.5.2 Merck & Co. Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Merck & Co. SWOT Analysis
2.5.4 Merck & Co. Product and Services
2.5.5 Merck & Co. Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Boehringer Ingelheim GmbH
2.6.1 Boehringer Ingelheim GmbH Details
2.6.2 Boehringer Ingelheim GmbH Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Boehringer Ingelheim GmbH SWOT Analysis
2.6.4 Boehringer Ingelheim GmbH Product and Services
2.6.5 Boehringer Ingelheim GmbH Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 AstraZeneca
2.7.1 AstraZeneca Details
2.7.2 AstraZeneca Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 AstraZeneca SWOT Analysis
2.7.4 AstraZeneca Product and Services
2.7.5 AstraZeneca Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Neurological Disorder Drugs Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Neurological Disorder Drugs Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Neurological Disorder Drugs Manufacturer Market Share in 2019
3.3.2 Top 6 Neurological Disorder Drugs Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Neurological Disorder Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Neurological Disorder Drugs Sales and Market Share by Regions (2015-2020)
4.1.2 Global Neurological Disorder Drugs Revenue and Market Share by Regions (2015-2020)
4.2 North America Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
4.3 Europe Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
4.5 South America Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Neurological Disorder Drugs Sales, Revenue and Market Share by Country
5.1.1 North America Neurological Disorder Drugs Sales and Market Share by Country (2015-2020)
5.1.2 North America Neurological Disorder Drugs Revenue and Market Share by Country (2015-2020)
5.2 United States Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
5.3 Canada Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
5.4 Mexico Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Neurological Disorder Drugs Sales, Revenue and Market Share by Country
6.1.1 Europe Neurological Disorder Drugs Sales and Market Share by Country (2015-2020)
6.1.2 Europe Neurological Disorder Drugs Revenue and Market Share by Country (2015-2020)
6.2 Germany Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
6.3 UK Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
6.4 France Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
6.5 Russia Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
6.6 Italy Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Neurological Disorder Drugs Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Neurological Disorder Drugs Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Neurological Disorder Drugs Revenue and Market Share by Regions (2015-2020)
7.2 China Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
7.3 Japan Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
7.4 Korea Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
7.5 India Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
7.7 Australia Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Neurological Disorder Drugs Sales, Revenue and Market Share by Country
8.1.1 South America Neurological Disorder Drugs Sales and Market Share by Country (2015-2020)
8.1.2 South America Neurological Disorder Drugs Revenue and Market Share by Country (2015-2020)
8.2 Brazil Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
8.3 Argentina Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Neurological Disorder Drugs Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Neurological Disorder Drugs Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Neurological Disorder Drugs Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
9.3 Turkey Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
9.4 Egypt Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
9.5 South Africa Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Neurological Disorder Drugs Sales and Market Share by Type (2015-2020)
10.2 Global Neurological Disorder Drugs Revenue and Market Share by Type (2015-2020)
10.3 Global Neurological Disorder Drugs Price by Type (2015-2020)
11 Global Neurological Disorder Drugs Market Segment by Application
11.1 Global Neurological Disorder Drugs Sales Market Share by Application (2015-2020)
11.2 Global Neurological Disorder Drugs Revenue Market Share by Application (2015-2020)
11.3 Global Neurological Disorder Drugs Price by Application (2015-2020)
12 Market Forecast
12.1 Global Neurological Disorder Drugs Sales, Revenue and Growth Rate (2021-2025)
12.2 Neurological Disorder Drugs Market Forecast by Regions (2021-2025)
12.2.1 North America Neurological Disorder Drugs Market Forecast (2021-2025)
12.2.2 Europe Neurological Disorder Drugs Market Forecast (2021-2025)
12.2.3 Asia-Pacific Neurological Disorder Drugs Market Forecast (2021-2025)
12.2.4 South America Neurological Disorder Drugs Market Forecast (2021-2025)
12.2.5 Middle East & Africa Neurological Disorder Drugs Market Forecast (2021-2025)
12.3 Neurological Disorder Drugs Market Forecast by Type (2021-2025)
12.3.1 Global Neurological Disorder Drugs Sales Forecast by Type (2021-2025)
12.3.2 Global Neurological Disorder Drugs Market Share Forecast by Type (2021-2025)
12.4 Neurological Disorder Drugs Market Forecast by Application (2021-2025)
12.4.1 Global Neurological Disorder Drugs Sales Forecast by Application (2021-2025)
12.4.2 Global Neurological Disorder Drugs Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Neurological Disorder Drugs Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Neurological Disorder Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Neurological Disorder Drugs Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 8. Novartis AG Neurological Disorder Drugs Major Business
Table 9. Novartis AG Neurological Disorder Drugs Total Revenue (USD Million) (2018-2019)
Table 10. Novartis AG SWOT Analysis
Table 11. Novartis AG Neurological Disorder Drugs Product and Services
Table 12. Novartis AG Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Bayer AG Basic Information, Manufacturing Base and Competitors
Table 14. Bayer AG Neurological Disorder Drugs Major Business
Table 15. Bayer AG Neurological Disorder Drugs Total Revenue (USD Million) (2018-2019)
Table 16. Bayer AG SWOT Analysis
Table 17. Bayer AG Neurological Disorder Drugs Product and Services
Table 18. Bayer AG Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. GlaxoSmithKline plc Basic Information, Manufacturing Base and Competitors
Table 20. GlaxoSmithKline plc Neurological Disorder Drugs Major Business
Table 21. GlaxoSmithKline plc Neurological Disorder Drugs Total Revenue (USD Million) (2018-2019)
Table 22. GlaxoSmithKline plc SWOT Analysis
Table 23. GlaxoSmithKline plc Neurological Disorder Drugs Product and Services
Table 24. GlaxoSmithKline plc Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Teva Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 26. Teva Pharmaceutical Neurological Disorder Drugs Major Business
Table 27. Teva Pharmaceutical Neurological Disorder Drugs Total Revenue (USD Million) (2018-2019)
Table 28. Teva Pharmaceutical SWOT Analysis
Table 29. Teva Pharmaceutical Neurological Disorder Drugs Product and Services
Table 30. Teva Pharmaceutical Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. Merck & Co. Basic Information, Manufacturing Base and Competitors
Table 32. Merck & Co. Neurological Disorder Drugs Major Business
Table 33. Merck & Co. Neurological Disorder Drugs Total Revenue (USD Million) (2018-2019)
Table 34. Merck & Co. SWOT Analysis
Table 35. Merck & Co. Neurological Disorder Drugs Product and Services
Table 36. Merck & Co. Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Boehringer Ingelheim GmbH Basic Information, Manufacturing Base and Competitors
Table 38. Boehringer Ingelheim GmbH Neurological Disorder Drugs Major Business
Table 39. Boehringer Ingelheim GmbH Neurological Disorder Drugs Total Revenue (USD Million) (2018-2019)
Table 40. Boehringer Ingelheim GmbH SWOT Analysis
Table 41. Boehringer Ingelheim GmbH Neurological Disorder Drugs Product and Services
Table 42. Boehringer Ingelheim GmbH Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 44. AstraZeneca Neurological Disorder Drugs Major Business
Table 45. AstraZeneca Neurological Disorder Drugs Total Revenue (USD Million) (2018-2019)
Table 46. AstraZeneca SWOT Analysis
Table 47. AstraZeneca Neurological Disorder Drugs Product and Services
Table 48. AstraZeneca Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. Global Neurological Disorder Drugs Sales by Manufacturer (2018-2019) (K Units)
Table 50. Global Neurological Disorder Drugs Revenue by Manufacturer (2018-2019) (USD Million)
Table 51. Global Neurological Disorder Drugs Sales by Regions (2015-2020) (K Units)
Table 52. Global Neurological Disorder Drugs Sales Market Share by Regions (2015-2020)
Table 53. Global Neurological Disorder Drugs Revenue by Regions (2015-2020) (USD Million)
Table 54. North America Neurological Disorder Drugs Sales by Countries (2015-2020) (K Units)
Table 55. North America Neurological Disorder Drugs Sales Market Share by Countries (2015-2020)
Table 56. North America Neurological Disorder Drugs Revenue by Countries (2015-2020) (USD Million)
Table 57. North America Neurological Disorder Drugs Revenue Market Share by Countries (2015-2020)
Table 58. Europe Neurological Disorder Drugs Sales by Countries (2015-2020) (K Units)
Table 59. Europe Neurological Disorder Drugs Sales Market Share by Countries (2015-2020)
Table 60. Europe Neurological Disorder Drugs Revenue by Countries (2015-2020) (USD Million)
Table 61. Asia-Pacific Neurological Disorder Drugs Sales by Regions (2015-2020) (K Units)
Table 62. Asia-Pacific Neurological Disorder Drugs Sales Market Share by Regions (2015-2020)
Table 63. Asia-Pacific Neurological Disorder Drugs Revenue by Regions (2015-2020) (USD Million)
Table 64. South America Neurological Disorder Drugs Sales by Countries (2015-2020) (K Units)
Table 65. South America Neurological Disorder Drugs Sales Market Share by Countries (2015-2020)
Table 66. South America Neurological Disorder Drugs Revenue by Countries (2015-2020) (USD Million)
Table 67. South America Neurological Disorder Drugs Revenue Market Share by Countries (2015-2020)
Table 68. Middle East & Africa Neurological Disorder Drugs Sales by Countries (2015-2020) (K Units)
Table 69. Middle East & Africa Neurological Disorder Drugs Sales Market Share by Countries (2015-2020)
Table 70. Middle East & Africa Neurological Disorder Drugs Revenue by Countries (2015-2020) (USD Million)
Table 71. Middle East & Africa Neurological Disorder Drugs Revenue Market Share by Countries (2015-2020)
Table 72. Global Neurological Disorder Drugs Sales by Type (2015-2020) (K Units)
Table 73. Global Neurological Disorder Drugs Sales Share by Type (2015-2020)
Table 74. Global Neurological Disorder Drugs Revenue by Type (2015-2020) (USD Million)
Table 75. Global Neurological Disorder Drugs Revenue Share by Type (2015-2020)
Table 76. Global Neurological Disorder Drugs Sales by Application (2015-2020) (K Units)
Table 77. Global Neurological Disorder Drugs Sales Share by Application (2015-2020)
Table 78. Global Neurological Disorder Drugs Sales Forecast by Regions (2021-2025) (K Units)
Table 79. Global Neurological Disorder Drugs Market Share Forecast by Regions (2021-2025)
Table 80. Global Neurological Disorder Drugs Sales Forecast by Type (2021-2025) (K Units)
Table 81. Global Neurological Disorder Drugs Market Share Forecast by Type (2021-2025)
Table 82. Global Neurological Disorder Drugs Sales Forecast by Application (2021-2025)
Table 83. Global Neurological Disorder Drugs Market Share Forecast by Application (2021-2025)
Table 84. Direct Channel Pros & Cons
Table 85. Indirect Channel Pros & Cons
Table 86. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Neurological Disorder Drugs Picture
Figure 2. Global Sales Market Share of Neurological Disorder Drugs by Type in 2019
Figure 3. Antipsychotic Picture
Figure 4. Hypnotic & Sedative Picture
Figure 5. Analgesics Picture
Figure 6. Anticoagulants Picture
Figure 7. Others Picture
Figure 8. Neurological Disorder Drugs Sales Market Share by Application in 2018
Figure 9. Hospital Picture
Figure 10. Clinic Picture
Figure 11. Global Neurological Disorder Drugs Market Status and Outlook (2015-2025) (USD Million)
Figure 12. United States Neurological Disorder Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 13. Canada Neurological Disorder Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 14. Mexico Neurological Disorder Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 15. Germany Neurological Disorder Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 16. France Neurological Disorder Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 17. UK Neurological Disorder Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 18. Russia Neurological Disorder Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 19. Italy Neurological Disorder Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 20. China Neurological Disorder Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Japan Neurological Disorder Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Korea Neurological Disorder Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 23. India Neurological Disorder Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Southeast Asia Neurological Disorder Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Australia Neurological Disorder Drugs Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 26. Brazil Neurological Disorder Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Egypt Neurological Disorder Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Saudi Arabia Neurological Disorder Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 29. South Africa Neurological Disorder Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Turkey Neurological Disorder Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 31. Global Neurological Disorder Drugs Sales Market Share by Manufacturer in 2019
Figure 32. Global Neurological Disorder Drugs Revenue Market Share by Manufacturer in 2019
Figure 33. Top 3 Neurological Disorder Drugs Manufacturer (Revenue) Market Share in 2019
Figure 34. Top 6 Neurological Disorder Drugs Manufacturer (Revenue) Market Share in 2019
Figure 35. Key Manufacturer Market Share Trend
Figure 36. Global Neurological Disorder Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 37. Global Neurological Disorder Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 38. Global Neurological Disorder Drugs Revenue Market Share by Regions (2015-2020)
Figure 39. Global Neurological Disorder Drugs Revenue Market Share by Regions in 2018
Figure 40. North America Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
Figure 41. Europe Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
Figure 42. Asia-Pacific Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
Figure 43. South America Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
Figure 44. Middle East & Africa Neurological Disorder Drugs Sales and Growth Rate (2015-2020)
Figure 45. North America Neurological Disorder Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 46. North America Neurological Disorder Drugs Sales Market Share by Countries (2015-2020)
Figure 47. North America Neurological Disorder Drugs Sales Market Share by Countries in 2018
Figure 48. North America Neurological Disorder Drugs Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 49. North America Neurological Disorder Drugs Revenue Market Share by Countries in 2018
Figure 50. United States Neurological Disorder Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 51. Canada Neurological Disorder Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 52. Mexico Neurological Disorder Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 53. Europe Neurological Disorder Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 54. Europe Neurological Disorder Drugs Revenue Market Share by Countries (2015-2020)
Figure 55. Europe Neurological Disorder Drugs Revenue Market Share by Countries in 2019
Figure 56. Germany Neurological Disorder Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 57. UK Neurological Disorder Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 58. France Neurological Disorder Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 59. Russia Neurological Disorder Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 60. Italy Neurological Disorder Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 61. Asia-Pacific Neurological Disorder Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 62. Asia-Pacific Neurological Disorder Drugs Sales Market Share by Regions 2019
Figure 63. Asia-Pacific Neurological Disorder Drugs Revenue Market Share by Regions 2019
Figure 64. China Neurological Disorder Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 65. Japan Neurological Disorder Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 66. Korea Neurological Disorder Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 67. India Neurological Disorder Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 68. Southeast Asia Neurological Disorder Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 69. South America Neurological Disorder Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 70. South America Neurological Disorder Drugs Sales Market Share by Countries in 2019
Figure 71. South America Neurological Disorder Drugs Revenue Market Share by Countries in 2019
Figure 72. Brazil Neurological Disorder Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 73. Argentina Neurological Disorder Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 74. Middle East and Africa Neurological Disorder Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 75. Middle East and Africa Neurological Disorder Drugs Sales Market Share by Countries in 2019
Figure 76. Middle East and Africa Neurological Disorder Drugs Revenue Market Share by Countries (2015-2020)
Figure 77. Middle East and Africa Neurological Disorder Drugs Revenue Market Share by Countries in 2019
Figure 78. Saudi Arabia Neurological Disorder Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 79. Egypt Neurological Disorder Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 80. Turkey Neurological Disorder Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 81. South Africa Neurological Disorder Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 82. Global Neurological Disorder Drugs Sales and Growth Rate (2021-2025) (K Units)
Figure 83. Global Neurological Disorder Drugs Revenue and Growth Rate (2021-2025) (USD Million)
Figure 84. North America Sales Neurological Disorder Drugs Market Forecast (2021-2025) (K Units)
Figure 85. Europe Sales Neurological Disorder Drugs Market Forecast (2021-2025) (K Units)
Figure 86. Asia-Pacific Sales Neurological Disorder Drugs Market Forecast (2021-2025) (K Units)
Figure 87. South America Sales Neurological Disorder Drugs Market Forecast (2021-2025) (K Units)
Figure 88. Middle East & Africa Sales Neurological Disorder Drugs Market Forecast (2021-2025) (K Units)
Figure 89. Sales Channel: Direct Channel vs Indirect Channel
双極性障害治療薬の世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The global Bipolar Disorder Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Bipolar Disorder Drugs…- 双極性障害治療の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Bipolar Disorder Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 1.9% in the forecast period of 2020 to 2025 and will expected to reach USD 4283.5 million by 2025, from USD 3966.9 million in 2019. The Bipola…
- 脂質障害治療の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Lipid Disorder Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 6.1% in the forecast period of 2020 to 2025 and will expected to reach USD 26310 million by 2025, from USD 20740 million in 2019. The Lipid Disorde…
- 大鬱病性障害の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Major Depressive Disorder market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Major Depressive Di…
- 大うつ病性障害（MDD）の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Major Depressive Disorder (MDD) market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Major Depress…